Skip to content
Menu

Sanofi SNY

Full chart Compare
Set alert

Price alert · SNY

All alert types
47.53 USD -0.86 (-1.78%)

Regular-session close

47.42 -0.11 -0.23%

Pre-market · Nov 18, 6:36 AM ET

47.50 Day range 47.96
39.07 52-week range 50.61
YTD
-1.92%
1 year
-6.18%
Market cap
114.13B
Revenue (ttm)
50.98B
Profit margin
8.19%
EPS (ttm)
2.01
Shares out
2.40B
P/E ratio
23.65
Forward P/E
8.76
Dividend
2.42 (3.64%)
Ex-dividend date
May 4, 2026
YTD return
-1.92%
1-year return
-6.18%
Volume
1.77M
Avg volume
3.33M
Open
47.54
Previous close
48.39
Day's range
47.50 – 47.96
52-week range
39.07 – 50.61
Beta
0.26
Analysts
Buy
Price target
54.92 (+15.6%)
Earnings date
Feb 4, 2027
50-day average
42.76

5D 0.00 (0.00%)

47.504848.5049WedThuFriMonTue47.67

Key statistics

200-day average
44.37
Enterprise value
130.38B
PEG ratio
2.97
Price / sales
2.24
Price / book
1.39
Payout ratio
119.86%
Revenue growth
15.70%
Free cash flow
8.27B
Total cash
5.97B
Total debt
19.84B
Return on equity
5.72%
Short % of float
0.58%

Fundamental scorecard

21 of 25 checks passed on SNY’s reported financials

ValueGrowthProfitabilityHealthDividend

21of 25 checks passed

  • Value 5 of 5
  • Growth 3 of 5
  • Profitability 4 of 5
  • Financial health 4 of 5
  • Dividend 5 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
SNY Revenue — annual 46.72B
SNY Net income — annual 7.81B
SNY EPS — annual 3.20

Earnings

SNY recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 4, 2027Dec 30, 20260.94———
Oct 30, 2026Sep 30, 20261.632.04+0.41+25.15%
Jul 30, 2026Jun 30, 20261.101.21+0.11+10.00%
Apr 23, 2026Mar 31, 20261.061.10+0.04+3.77%
Jan 29, 2026Dec 31, 20250.840.89+0.05+5.95%
Oct 24, 2025Sep 30, 20251.601.70+0.10+6.25%

Upgrades / downgrades

SNY analyst upgrades and downgrades
DateFirmActionFromTo
Jan 16, 2026UBSdownBuyNeutral
Jan 6, 2026BarclaysdownOverweightEqual-Weight
Dec 9, 2025GuggenheimdownBuyNeutral
Dec 8, 2025JP MorgandownOverweightNeutral
Sep 8, 2025Morgan StanleyupEqual-WeightOverweight
Sep 2, 2025Deutsche BankupHoldBuy

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
France
Website
sanofi.com

News

Your note

Sign in to keep a note on SNY — it syncs with the Stock Master app.

Institution ownership

SNY institution ownership
Holder% heldSharesValueReported
Dodge & Cox Inc.5.88%15,668,529744.73MSep 29, 2026
Morgan Stanley5.59%14,900,060708.20MSep 29, 2026
Fisher Asset Management, LLC3.60%9,597,228456.16MSep 29, 2026
Bank of America Corporation2.94%7,840,212372.65MSep 29, 2026
JPMORGAN CHASE & CO2.75%7,330,737348.43MSep 29, 2026
Invesco Ltd.2.35%6,271,955298.11MSep 29, 2026

Fund ownership

SNY fund ownership
Holder% heldSharesValueReported
Dodge & Cox Funds-Dodge & Cox Stock Fund7.84%20,904,624993.60MJun 29, 2026
AIM Sector Funds (Invesco Sector Funds)-INVESCO COMSTOCK FUND1.51%4,026,820191.39MJul 30, 2026
Dodge & Cox Funds-Dodge & Cox Balanced Fund0.63%1,673,46579.54MJun 29, 2026
American Century ETF Trust-Avantis International Equity ETF0.38%1,009,51247.98MSep 29, 2026
Bridge Builder Trust-Bridge Builder Large Cap Value Fund0.36%967,10045.97MJun 29, 2026
Fidelity Commonwealth Trust II-Fidelity Enhanced International ETF0.33%884,92142.06MSep 29, 2026